JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.51 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $832,000 | +24.9% | 18,550 | -16.8% | 0.01% | +25.0% |
Q2 2017 | $666,000 | +35.9% | 22,285 | +1.0% | 0.00% | +33.3% |
Q1 2017 | $490,000 | +20.7% | 22,060 | +2.3% | 0.00% | 0.0% |
Q4 2016 | $406,000 | -40.7% | 21,560 | -5.6% | 0.00% | -40.0% |
Q3 2016 | $685,000 | -24.3% | 22,838 | -3.0% | 0.01% | -37.5% |
Q2 2016 | $905,000 | +10.5% | 23,541 | +9.4% | 0.01% | +14.3% |
Q1 2016 | $819,000 | +7.3% | 21,510 | +23.9% | 0.01% | 0.0% |
Q4 2015 | $763,000 | +19.8% | 17,360 | +10.9% | 0.01% | 0.0% |
Q3 2015 | $637,000 | +29.7% | 15,660 | +70.2% | 0.01% | +40.0% |
Q2 2015 | $491,000 | +33.8% | 9,200 | +52.1% | 0.01% | +25.0% |
Q1 2015 | $367,000 | – | 6,050 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |